Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks
Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the swiss health care system
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the swiss health care system
Journal
Value in health
Volume
15
Number
1
Pages / Article-Number
65-71
Keywords
best supportive care, cost-effectiveness, health economics, lung cancer, pemetrexed, maintenance treatment
Abstract
A recent randomized study showed switch maintenance with pemetrexed after nonpemetrexed-containing first-line chemotherapy in patients with advanced nonsmall-cell lung cancer to prolong overall survival by 2.8 months. We examined the cost-effectiveness of pemetrexed in this indication, from the perspective of the Swiss health care system, and assessed the influence of the costs of best supportive care (BSC) on overall cost-effectiveness.
